Granulocyte-colony stimulating factor for acute-on-chronic liver failure: systematic review and meta-analysis.

Abstract

Acute-on-chronic liver failure (ACLF) is associated with increased short and long-term mortality. Animal models of liver failure have demonstrated that granulocyte-colony stimulating factor (G-CSF) accelerates the liver regeneration process and improves survival. However, clinical evidence regarding the use of G-CSF in ACLF remains scarce. The aim of this study was to assess the benefits and harms of G-CSF in patients with acute-on-chronic liver failure. An electronic search was made in The Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and LILACS up to November 2013. Randomized clinical trials comparing the use of any regimen of G-CSF against placebo or no intervention in patients with ACLF were included. Primary outcomes included overal mortality, mortality due multi-organ failure, and adverse events. Relative risk (RR) and mean difference (MD) were used. Two trials involving 102 patients were included. A significant reduction in short-term overall mortality was observed in patients receiving G-CSF compared to controls (RR 0.56; 95%CI 0.39,0.80). G-CSF failed to reduce mortality secondary to gastrointestinal bleeding (RR 1.45; 95%CI 0.50, 4.27). Adverse effects reported included: fever, rash, herpes zoster, headache and nausea. In conclusion, the use of G-CSF for the treatment of patients with ACLF significantly reduced short-term mortality. While the evidence is still limited, the apparent benefit observed on short-term mortality, mild adverse effects and lack of an alternative therapy make the use of G-CSF in ACLF patients a reasonable alternative when liver transplantation is contraindicated or unavailable.

• Authors: Norberto C Chavez-Tapia, Indira Mendiola-Pastrana, Victoria J Ornelas-Arroyo, Camilo Noreña-Herrera, Desiree Vidaña-Perez, Guadalupe Delgado-Sanchez, Misael Uribe, Tonatiuh Barrientos-Gutierrez
• Journal: Annals of hepatology (Ann Hepatol) 2015 Sep-Oct Vol. 14 Issue 5 Pg. 631-41 ISSN: 1665-2681 [Print] Mexico
• PMID: 26256891 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)

Chemical References

• Filgrastim

Topics

• Acute-On-Chronic Liver Failure (diagnosis, drug therapy, mortality)
• Cause of Death
• Chi-Square Distribution
• Disease Progression
• Filgrastim (adverse effects, therapeutic use)
• Humans
• Multiple Organ Failure (mortality)
• Odds Ratio
• Risk Assessment
• Risk Factors
• Severity of Illness Index
• Survival Analysis
• Time Factors
• Treatment Outcome